Breast Elasticity Imaging During Neoadjuvant Chemotherapy

For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.

Trial Details

NCT ID
NCT04824027
Phase
NA
Sponsor
Columbia University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Harmonic motion imaging
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Women age 18 years or older
  • Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treatin…
  • Any stage invasive breast cancer provided the primary breast tumor size is at least 4 mm

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →